Purpose: Proinflammatory cytokines, such as IL-1 and tumor necrosis factor a (TNFa), are suspected of causing damage to osteoarthritis (OA) cartilage. TNFa content is elevated in the synovial fluid of OA joints. There are 2 cell surface receptors for TNFa including p55 (TNFRI) and p75 (TNFRII). TNFa and TNFRs I and II are up-regulated in OA cartilage. For bone metabolism, mice null for TNFR1 have significantly increased peak bone mass, resulting from elevated bone formation. In vitro, TNFa inhibited mineralization of osteoblasts through regulation of NF-kB activity. Thus, whereas TNFR1 plays roles in osteoblast differentiation, its functions in chondrocyte metabolism is unknown. Endochondral ossification is an essential process for development of OA, which is characterized by cartilage degradation and osteophyte formation. The aim of this study is to investigate the role of TNFR1 in the maintenance of articular tissues. Materials and Methods: Histological evaluation of aged TNFR1−/− mice: Knee joints of TNFR1−/− and their wild-type (WT) littermates (52-60 weeks of age) were evaluated immunohistologicaly. Whole knee joints were removed by dissection, fixed in 4% paraformaldehyde, and decalcified in EDTA. After dehydration and paraffin embedding, serial 5-mm sagittal sections were made from the whole medial compartment of the knee joint. Three sections were picked up at 100-mm intervals from the weight-bearing region of each medial plateau of tibia, and were stained with Safranin O-fast green and HE. Osteophyte area and articular cartilage thickness were quantified in each slide using Image-Pro Plus 4.1 software. Surgical induction of OA in TNFR1−/− mice: TNFR1−/− and their wild-type (WT) littermates were surgically induced to develop OA by medial collateral ligament transection and medial meniscectomy. Four weeks after surgery, the mice were euthanized. Results: At 52-60 weeks of age, whereas osteophyte formation was detected at the medio-anterior edge of tibial plateau regardless of genotype, osteophyte area was significantly increased in TNFR1−/− mice. Moreover, articular cartilage thickness was reduced at medial end region of tibia plateau in TNFR1−/− mice, suggesting ossification of articular chondrocyte was advanced by TNFR1 deficiency. We next compared osteoarthritis development between adult littermates of wild-type and TNFR1−/− mice by creating a surgical osteoarthritis model through induction of instability to the knee joints. Histological evaluation confirmed that the TNFR1 deficiency caused significant acceleration for osteophyte formation. Degree of cartilage destruction was almost comparable between TNFR1−/− and WT. Real time PCR analysis for epiphyseal chondrocyte from new born mice revealed mRNA expression of type X collagen, a marker for chondrocyte hypertrophy, was significantly elevated in TNFR1−/− mice compared to WT littermate. Currently, we are picking up a number of candidate genes for targets of TNFR1 in the course of chondrocyte hypertrophy using cDNA microarray analysis. Conclusion: Endogenous TNFR1 had a protective effect against osteophyte formation through inhibition of type X collagen synthesis. Purpose: Pro-and anti-inflammatory factors in the synovial fluid play a role in osteoarthritis (OA), although the exact pathogenesis is still unclear. One of these factors may be oncostatin M (OSM). OSM, a proinflammatory cytokine of the IL-6 family. OSM has been demonstrated to play a role in cartilage degeneration, bone turnover and synovial inflammation in rheumatoid arthritis, however, its role in OA remains unclear. The current study aimed to investigate the presence of OSM in OA synovial fluid and its role in osteoarthritic cartilage degeneration. Methods: The OSM concentration in the synovial fluid (SF) of 32 OA patients and 24 healthy donors was determined by ELISA. The presence of receptors for OSM in osteoarthritic and healthy cartilage explants was determined by immunohistochemistry for the OSM-and LIF-receptor.
To study the role of OSM in OA cartilage degeneration, OA cartilage explants of 5 donors were cultured for 14 days with and without 25% OA synovial fluid of multiple OA donors, and with or without addition of a blocking antibody against OSM. To determine if the OSM concentrations, as present in OA SF, could exert a direct effect on cartilage metabolism, recombinant OSM was added at these concentration. Cartilage metabolism was determined by glycosaminoglycans (GAG) content and release. For statistical analysis, univariate analysis of variance was performed. To correct for inter-donor variability a randomized block design was used. P values <0.05 were considered significant. Results: The concentration of OSM in SF of osteoarthritic donors ranged from 0-570 pg/ml (average 39 pg/ml). In healthy SFs, OSM concentration was significantly lower, and was only detected in one donor (figure 1; P < 0.001). Immunohistochemistry confirmed the presence of both the LIF receptor and OSM receptor in osteoarthritic cartilage and healthy cartilage. In healthy cartilage, only the cells in the superficial layer showed positive staining for both receptors, whereas in osteoarthritic cartilage positive cells for both receptors were found throughout the entire depth of the cartilage. Blocking OSM in osteoarthritic SF increased GAG content compared to cartilage explants cultured with SF alone (figure 1; P < 0.05). Recombinant OSM alone at a concentration of 5 or 50 pg/ml did not show an effect on cartilage metabolism. Only a high concentration of OSM (10 ng/ml) could decrease GAG content (data not shown; P < 0.05).
Conclusions:
OSM is present at increased levels in synovial fluid of osteoarthritis patients compared to synovial fluid of healthy donors. Moreover, the expressions of receptors for OSM appeared to be increased in osteoarthritic cartilage. Blocking OSM in the synovial fluid of OA patients increases GAG content of OA cartilage explants. OSM at concentrations present in OA SF does not affect cartilage metabolism, suggesting that the effect is not direct, but OSM works in concert with other factors in the synovial fluid. OSM might be a target for future therapy to inhibit cartilage degeneration in OA. Fig. 1 . Concentration of OSM in SF (*P < 0.001). Increase of GAG content when OSM is blocked in SF (*P < 0.05).
